11/4/2021

speaker
Operator
Conference Call Operator

Good afternoon and welcome to APRIA's third quarter 2021 earnings conference call and webcast. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question, you will need to press star then one on your telephone. Please note this event is being recorded. Leading today's call are Dan Stark, Chief Executive Officer, and Debbie Morris, Chief Financial Officer. Before we begin, we would like to remind you that certain statements made during this call will be forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are subject to various risks and uncertainties and reflect our current expectations based on our beliefs, assumptions, and information currently available to us. Although we believe these expectations are reasonable, we undertake no obligation to revise any statement that reflect changes that occur after this call. Descriptions of some of the factors that could cause action results to differ materially from these forward-looking statements can be found in the risk factor section of the company's annual report on Form 10-K for the year ended December 31, 2020, as supplemented by APRIA's quarterly reports on Form 10-Q for the periods ended June 30, 2021 and September 30, 2021, the latter of which is expected to be filed later today. In addition, please note that the company will be discussing certain non-GAAP financial measures that they believe are important in evaluating performances. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliation of historical non-GAAP financial measures can be found in the press release that is posted on the investor section of the company's website at www.apria.com. With that, I'd like to turn the call over to Apria CEO, Dan Stark. Please go ahead.

speaker
Dan Stark
Chief Executive Officer

Thank you, operator. Welcome, and thank you all for joining us this afternoon to discuss our third quarter 2021 earnings results. I'm joined today by Debbie Morris, our Chief Financial Officer. I'll begin my remarks with some high-level comments on our results from the quarter, discuss some underlying trends and other activities in our business, as well as provide some thoughts on an industry-wide initiative that could have a meaningful impact on our business and the D&E industry over the long term. Then Debbie will provide a more detailed review of the financials and our guidance later on the call. Building on the momentum from the first half of the year and despite external headwinds, we delivered another solid quarter with revenue that was in line with our expectations while adjusted EBITDA and adjusted EBITDA-less PSE CapEx were at the high end or better than our guidance range. Our quarterly performance is reflective of our continued execution and operational improvements, coupled with the continued recovery in new patient volumes, despite significant industry disruption related to the Philips product recall and supply chain issues impacting other manufacturers. Third quarter revenue grew to $287.2 million, a 3.8% increase over Q3 2020. Adjusted EBITDA was 61 million, a 6% decrease from Q3 2020. And adjusted EBITDA less patient equipment capex grew to 38.9 million, a slight increase over Q3 2020. The surge from the Delta variant provided a meaningful boost in our new oxygen patient volume in the third quarter. The spike was so pronounced that new patient starts for oxygen per day in August was higher than any month during the peak of the COVID pandemic last winter. Now, keeping in line with the prevalence of the Delta variant, we have started to see new oxygen patient volumes decrease, but they are still at elevated levels compared to historical run rates. I'm proud of the entire organization for their perseverance in the face of difficult challenges. The APRIA team continues to execute at a high level and continues to deliver on our mission of improving the quality of life for our patients at home. While other potential issues could arise in the future, I have great confidence that our team will be able to navigate any challenge and will continue to operate at a high level. Now, on to the business. First, I'd like to discuss the Philips Respironics recall and other supply chain issues impacting our results. As a reminder, in June, Philips announced a voluntary recall for continuous and non-continuous ventilators. certain BiPAP, CPAP, bi-level positive airway pressure, and ventilator devices, all related to the polyurethane foam used in those devices. The recall notice instructed CPAP and BiPAP patients to discontinue use of their device and consult with their physician to determine the benefits of continuing therapy and potential risks. Ventilation patients were instructed to continue using their device and to consult with their physician to determine the appropriate next steps. To date, we have not experienced a significant number of patients stopping their therapy. In early September, Philips began the remediation process for CPAP and BiPAP units, and the process of repairing and or replacing those units is now underway. However, as of today, there has not been an approved remediation process for ventilators. We expect the CPAP remediation to continue into 2022. and we are hopeful that the ventilation remediation process will begin sometime this quarter. The supply chain disruption has also impacted our primary source of sleep equipment. Consistent with the rest of the industry, in the third quarter, we were on an allocation process based on historic purchases. Our allocation increased throughout Q3, but was below historic levels, thus impacting equipment availability for new patient starts. At the end of the quarter, we did identify another source for sleep equipment, and we started receiving units in mid-October. During the third quarter, we experienced a surge in incoming new patient volumes, which we believe bodes well for us as we increase our product inventory. Moving on to our operational performance, our team continues to execute at a high level, and as patient volumes and revenue have grown nicely throughout the year, we have been able to drive operating efficiencies. We have a very different situation in Q3 of 2021 than we had in Q3 of 2020. In Q3 2020, our incoming volumes were largely down, other than oxygen, which allowed us to flex down our variable costs. In Q3 2021, we have large incoming volume increases, which require processing and preparation for delivery, which don't allow us to flex down our variable costs. but the equipment availability challenges are delaying our revenue recognition. We expect that to work its way through as we increase our supply. From an M&A perspective, last quarter we announced the acquisition of Airway Breathing Company, which enhanced our presence in key markets in Virginia. I'm pleased to announce the ABC acquisition closed in September and is performing in line with our expectations. Our M&A pipeline remains active and robust, We look at deals of all sizes but take a measured approach and follow a rigorous evaluation process. We're looking to acquire strong local businesses that are financially attractive and are the right cultural fit for APRIA. One other item I'd like to discuss is a new industry initiative to help drive widespread adoption of e-prescribing. As some of you saw, in September, DME Scripps announced a strategic partnership with the four national DME providers Lincare, Apria, Adapt Health, and Rotec, as well as two industry trade associations, the American Association for Home Care and VGM, to help drive greater use and adoption of e-prescribe. We believe this is an important step in our industry and a significant step towards increasing widespread adoption of e-prescribe and DME. For too long, our industry has existed on a fax and paper-based legacy process for new referrals, which is fraught with multiple handoffs and friction points in the referral process. Currently, only a small amount of orders are transacted electronically, and while there's no forcing mechanism or mandate to get prescribers to switch to electronic ordering, we believe that a united industry message of moving to e-prescribe will accelerate the move to a future state. Our view is that this is a matter of when, not if, and that ePrescribe is the future for the industry. Widespread adoption of ePrescribe will help all constituents involved in the process, patients, referrals, and suppliers, by removing friction points and streamlining the referral process. Patients will receive equipment faster, while prescribers and suppliers will have less back and forth for needed documentation, which reduces the administrative burden for both. I suspect there will be questions about the financial impact. And what I can say is we are in the very early stages of this industry-wide initiative. Our aspiration is to see rapid and widespread adoption for ePrescribe. But realistically, we know this isn't something that will happen overnight. Rather, it will take some time to significantly increase adoption, and the benefits will increasingly grow over that time period. Yet we believe this will help drive meaningful efficiency and cost savings throughout the entire industry and for AFRIA. Before I turn the call over to Debbie, I'd like to provide a quick update or reminder regarding the current regulatory environment. First, the public health emergency has been extended for another 90 days until mid-January. As discussed before, the PHE provides an interim price increase for Medicare patients in the non-bid, non-rural areas of the country and keeps intact the 50-50 blended rate in the rural areas of the country. While the PHE extension was largely expected, the extension still needs to go through the mandatory process, and this is done in 90-day increments. In September, Medicare finalized a national coverage determination for oxygen that will expand home oxygen coverage and potentially reduce some of the administrative burden. Overall, the NCD is a positive for Medicare beneficiaries and the DME industry. And as a reminder, the suspension of sequestration was extended through year-end, and CMS permanently removed the budget neutrality rate adjustment or oxygen equipment that has resulted in a reimbursement rate increase for some oxygen systems. Both of these factors are tailwinds for APRIA, and we had already factored them into our guidance. To sum things up, we reported another solid quarter, and we are confident we'll be able to finish the year on a high note. Our industry is coming together to drive greater use of E-Prescribe, which will help drive operating efficiencies over the long run as adoption increases. Our team continues to execute at a high level, And while there have been some challenges such as the Phillips recall and other supply chain issues, we have been able to drive operational improvements and other efficiencies. I'd like to thank the entire Apria team for their dedication and hard work helping to drive these results. They are the heartbeat of Apria and they are the individuals that deliver our mission every day, improving the quality of life for our patients at home. I'll now turn the call over to Debbie to review our financial performance in more detail and provide our outlook for 2021.

speaker
Debbie Morris
Chief Financial Officer

Thank you, Dan, and thank you to everyone who joined the call today. We delivered another solid quarter with third quarter revenue that was in line with our expectations and adjusted EBITDA and adjusted EBITDA-less patient CapEx, which was at or above the high end of our prior guidance. Our strong performance was driven by solid operational performance despite the surge in Delta variant and despite significant industry disruption related to the Philips product recall and supply chain issues impacting other manufacturers. Net revenue of $287.2 million was slightly higher than the midpoint of our guidance range. Adjusted EBITDA of $61 million was at the high end of our guidance range, and adjusted EBITDA less patient equipment CapEx of $38.9 million was modestly ahead of our guidance range for the third quarter. We experienced strong oxygen volume due to the Delta variant, and closed the ABC acquisition during the quarter, both of which contributed to exceeding the midpoint of our revenue guidance. In addition, our teams did a nice job of managing through the Phillips recall and supply chain shortages, and despite wage and cost pressures, adjusted EBITDA as a percent of net revenue was slightly higher than projected. Reviewing our third quarter results on a year-over-year basis, net revenue of $287.2 million increased 3.8% over Q3 2020. Excluding the airway breeding company acquisition, which closed in September, net revenue increased 3.5% year-over-year. The increase in net revenue is driven by growth in home respiratory therapy and OSA treatment. Home respiratory therapy was up 4.2% over prior year due to increased volume of patients requiring home oxygen therapy due to the Delta variant, and higher reimbursement levels, offset partially by lower ventilation therapy revenues due to COVID and the Phillips recall. OSA treatment was up 5.6% due to the increased volume of patients over prior year and increases in sleep supply, despite the reduction in new patients in the quarter as a result of the equipment shortages stemming from the recall and other supply chain challenges. Overall, net revenue growth was in line with our expectations provided last quarter, but lower on a sequential basis, largely due to the Phillips recall and supply chain challenges, which impacted sleep and non-invasive ventilation growth in Q3 of this year. Adjusted EBITDA in the quarter of $61 million was down 6.2% from $65 million in the third quarter of last year. As Dan mentioned, we had a very different situation in Q3 of 2021 than we had in Q3 2020. In Q3 of last year, our incoming volume was largely down, other than oxygen, which allowed us to flex down our variable costs. In Q3 of this year, we had larger incoming oxygen and sleep volume, which require incurring certain variable costs to process orders, qualify the patients, and prepare the orders for delivery. while the Phillips recall and supply chain challenges are delaying the setup of patients and related revenue recognition. In addition, other costs including distribution expenses, self-insurance, health costs, and costs of being public are up on a year-over-year basis. Adjusted EBITDA less patient equipment CapEx of 38.9 million was roughly in line with the third quarter 2020 of 38.6 million. While adjusted EBITDA was down year-over-year, Patient CapEx was also down year over year, given the recall and supply chain challenges and related shortage of equipment. Looking at the balance sheet, as of September 30, we had $216 million in cash and total debt of $382 million. Turning to our updated outlook for 2021, we have performed better than expected throughout the first three quarters of the year, despite some recent headwinds. We've continued to drive operating cost leverage, which has been better than projected throughout the year. The public health emergency has been extended through mid-January of next year. The suspension of sequestration was extended through year-end, and CMS permanently removed the budget neutrality rate adjustment for oxygen equipment that resulted in a reimbursement rate increase for some oxygen systems. We continue to spend extra time and resources to support our patient needs as it relates to the Phillips Respiratus recall. The labor issues facing healthcare in much of the country are impacting our business, and we're seeing some cost inflation in other parts of the business, including the supply chain and for certain DME equipment. We've been able to navigate and manage through these headwinds the last several months, and we've secured additional equipment in Q4 from another manufacturer. So we expect to see an increase in volume of sleep patients starting therapy. Looking ahead for the fourth quarter and full year 21, we've taken all these factors I just mentioned into consideration. For the fourth quarter of 2021, we expect net revenues of $282 million to $298 million. Adjusted EBITDA of $54 to $60 million. and adjusted EBITDA less patient equipment CapEx of $27 million to $31 million. For the full year 2021, we are increasing revenue in adjusted EBITDA guidance while narrowing the adjusted EBITDA less patient equipment CapEx guidance range, and we're now projecting the following financial results. Net revenue of $1.13 to $1.15 billion, up from $1.12 to $1.15 billion, Adjusted EBITDA of $228 to $234 million, up from $221 to $231 million. Adjusted EBITDA less patient equipment CapEx of $135 to $139 million, from $132 to $142 million. To sum things up, I'm pleased with our performance again this quarter and the other day. The APRIA team has and continues to perform well in the face of challenges. I, too, want to thank our entire team for their commitment to APRIA and to our patients and for delivering on our mission of improving the quality of life for our patients at home. Operator will now open it up for questions.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-